Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333300 | 0.64 | MAPT (0.42) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL17921637 | 0.62 | PLK1 (0.39) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL10426958 | 0.61 | TDP1 (0.53) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL29225055 | 0.61 | POLB (0.43) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL28725429 | 0.61 | POLB (0.40) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL24177880 | 0.61 | POLB (0.40) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16539381 | 0.61 | PLK1 (0.38) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL9803087 | 0.59 | CYP1A2 (0.51) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL23121598 | 0.59 | KMT2A (0.39) | MAOAMAOBCYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL3878191 | 0.58 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | claimed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | claimed |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-12-04 | — | — | US | claimed |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | claimed |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | claimed |
| EP-2794589-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794588-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794590-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794591-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794592-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| WO-2013096051-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096049-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096060-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096055-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096059-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2013-06-27 | — | — | WO | claimed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | MAOA 592/4885MAOB 736/4885CYP2A6 4034/4885 |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAOA 4604/4885MAOB 3814/4885CYP2A6 4001/4885 |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAOA 4604/4885MAOB 3814/4885CYP2A6 4001/4885 |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAOA 4604/4885MAOB 3814/4885CYP2A6 4001/4885 |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAOA 4604/4885MAOB 3814/4885CYP2A6 4001/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | MAOA 4588/4885MAOB 3824/4885CYP2A6 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.